These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
223 related items for PubMed ID: 6139399
21. [Clinical studies on abnormal thyroid stimulators in patients with Graves' disease. I. A sensitive assay for thyroid-stimulating antibodies using cultured porcine thyroid cells and polyethylene glycol precipitation of serum]. Uno C, Nishikawa M. Nihon Naibunpi Gakkai Zasshi; 1988 Mar 20; 64(3):193-205. PubMed ID: 2899523 [Abstract] [Full Text] [Related]
22. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. Kawai K, Tamai H, Matsubayashi S, Mukuta T, Morita T, Kubo C, Kuma K. Clin Endocrinol (Oxf); 1995 Nov 20; 43(5):551-6. PubMed ID: 8548939 [Abstract] [Full Text] [Related]
23. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Michelangeli V, Poon C, Taft J, Newnham H, Topliss D, Colman P. Thyroid; 1998 Feb 20; 8(2):119-24. PubMed ID: 9510119 [Abstract] [Full Text] [Related]
24. [The prognostic value of thyroid stimulating antibodies after antithyroid drug treatment of Graves' disease]. Li J, Gao H, Xu L. Zhonghua Yi Xue Za Zhi; 1994 Apr 20; 74(4):218-20, 254-5. PubMed ID: 7922762 [Abstract] [Full Text] [Related]
25. The effect of subtotal thyroidectomy with propranolol preparation on antibody activity in Graves' disease. Steel NR, Taylor JJ, Young ET, Farndon JR, Holcombe M, Kendall-Taylor P. Clin Endocrinol (Oxf); 1987 Jan 20; 26(1):97-106. PubMed ID: 3802553 [Abstract] [Full Text] [Related]
26. Clinical significance of a sensitive assay for thyroid-stimulating antibodies in Graves' disease using polyethylene glycol at high concentrations and porcine thyroid cells. Kamijo K, Nagata A, Sato Y. Endocr J; 1999 Jun 20; 46(3):397-403. PubMed ID: 10503992 [Abstract] [Full Text] [Related]
28. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease. Noh JY, Hamada N, Inoue Y, Abe Y, Ito K, Ito K. Thyroid; 2000 Sep 20; 10(9):809-13. PubMed ID: 11041459 [Abstract] [Full Text] [Related]
29. Comparison between thyroid stimulating and tsh-binding inhibiting immunoglobulins of Graves' disease. Macchia E, Fenzi GF, Monzani F, Lippi F, Vitti P, Grasso L, Bartalena L, Baschieri L, Pinchera A. Clin Endocrinol (Oxf); 1981 Aug 20; 15(2):175-82. PubMed ID: 6118213 [Abstract] [Full Text] [Related]
30. Thyrotrophin binding inhibiting immunoglobulins in Graves' disease before, during and after antithyroid therapy, and its relation to long-acting thyroid stimulator. Docter R, Bos G, Visser TJ, Hennemann G. Clin Endocrinol (Oxf); 1980 Feb 20; 12(2):143-53. PubMed ID: 6105023 [Abstract] [Full Text] [Related]
31. Thyroid response, especially to thyrotropin-binding inhibitory immunoglobulins, in euthyroid relatives of patients with Graves' disease: a clinical follow-up. Tamai H, Kasagi K, Morita T, Hidaka A, Kuma K, Konishi J, Kumagai LF, Nagataki S. J Clin Endocrinol Metab; 1990 Jul 20; 71(1):210-5. PubMed ID: 1973421 [Abstract] [Full Text] [Related]
32. Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease. Kasagi K, Hatabu H, Tokuda Y, Iida Y, Endo K, Konishi J. Clin Endocrinol (Oxf); 1988 Oct 20; 29(4):357-66. PubMed ID: 2908031 [Abstract] [Full Text] [Related]
33. Prognostic value of thyrotrophin binding inhibiting immunoglobulins (TBII) in longterm antithyroid treatment, 131I therapy given in combination with carbimazole and in euthyroid ophthalmopathy. Bliddal H, Kirkegaard C, Siersbaek-Nielsen K, Friis T. Acta Endocrinol (Copenh); 1981 Nov 20; 98(3):364-9. PubMed ID: 6170200 [Abstract] [Full Text] [Related]
34. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease. Yamano Y, Takamatsu J, Sakane S, Hirai K, Kuma K, Ohsawa N. Thyroid; 1999 Aug 20; 9(8):769-73. PubMed ID: 10482368 [Abstract] [Full Text] [Related]
35. Clinical validity of a new commercial method for detection of TSH-receptor binding antibodies in sera from patients with Graves' disease treated with antithyroid drugs. Massart C, Orgiazzi J, Maugendre D. Clin Chim Acta; 2001 Feb 20; 304(1-2):39-47. PubMed ID: 11165197 [Abstract] [Full Text] [Related]
36. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies. Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J, Morgenthaler NG. Clin Endocrinol (Oxf); 2004 Nov 20; 61(5):612-8. PubMed ID: 15521965 [Abstract] [Full Text] [Related]
37. Relationship among thyrotropin (TSH), thyroid stimulating immunoglobulins, and results of triiodothyronine (T3) suppression test in patients with Graves' disease. Horimoto M, Nishikawa M, Uno C, Yoshikawa N, Taniguchi N, Inada M. Endocrinol Jpn; 1988 Dec 20; 35(6):841-8. PubMed ID: 2471633 [Abstract] [Full Text] [Related]
39. Thyroid stimulating antibodies: an aid to the strategy of treatment of Graves' disease? Madec AM, Laurent MC, Lorcy Y, Le Guerrier AM, Rostagnat-Stefanutti A, Orgiazzi J, Allannic H. Clin Endocrinol (Oxf); 1984 Sep 20; 21(3):247-55. PubMed ID: 6148163 [Abstract] [Full Text] [Related]
40. [Detection of thyroid stimulating antibodies and TSH binding inhibitor immunoglobulins in patients with thyroid diseases and its clinical applications]. Liu C, Yin F, Zhang Z. Zhonghua Nei Ke Za Zhi; 1995 Feb 20; 34(2):105-7. PubMed ID: 7796654 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]